AAX Biotech provides proprietary platforms that streamline antibody drug development. Seqitope® delivers high‑resolution, high‑throughput epitope mapping for up to 100 monoclonal antibodies, while Opti‑mAb® stabilizes scFv formats to boost expression yields and reduce aggregation, supporting therapeutic and diagnostic antibody programs.
Funding
$681.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Antibody drug development faces two major bottlenecks: low‑resolution, low‑throughput epitope mapping that hampers target validation and lead selection, and instability of single‑chain variable fragment (scFv) formats that reduces expression yields and therapeutic performance, especially for bispecifics and CAR‑T cells.
Solution
AAX Biotech offers two proprietary platforms to address these challenges. Seqitope® provides high‑resolution, high‑throughput epitope mapping using massive parallel mutagenic scanning, enabling simultaneous analysis of up to 100 monoclonal antibodies and delivering detailed binding site data for lead optimization, patent filing, and regulatory submissions. Opti‑mAb® applies a broadly applicable molecular stabilization strategy to scFv antibodies, increasing production yields, eliminating aggregation, and improving developability for bispecifics, CAR‑T constructs, and diagnostic formats. Together, the technologies accelerate antibody discovery, reduce development costs, and improve the therapeutic and diagnostic utility of next‑generation antibody modalities.
Target Audience
Primary customers are pharmaceutical and biotech companies developing antibody‑based therapeutics or diagnostics, particularly those working on bispecifics, CAR‑T cell therapies, and high‑throughput antibody discovery programs.
Features
- Seqitope® high‑resolution epitope mapping based on massive parallel mutagenic scanning
- Ability to process up to 100 monoclonal antibody candidates in parallel, enabling high‑throughput workflows
- Generates data useful for lead selection, mechanism‑of‑action studies, patent positioning, and regulatory dossiers
- Opti‑mAb® molecular stabilization platform that enhances scFv stability, expression yields, and reduces aggregation
- Compatible with a wide range of scFv‑based formats, including bispecific antibodies, CAR‑T cell receptors, and lateral‑flow diagnostics
- Supports early‑stage antibody engineering through partnerships with service providers such as evitria AG
- Provides a single source of both epitope mapping and scFv stabilization to streamline antibody development pipelines